Soroush Sohrabi: The Hidden Biology of Sclerotherapy and Mechanisms Beyond Endothelial Injury
Soroush Sohrabi, Consultant vascular and ednovascular surgeon at NMC Healthcare, shared a post on LinkedIn:
“Sclerotherapy Reality Check: Blood Inactivates — and the Vein Wall Matters
We often describe sclerotherapy in simple terms: inject the sclerosant, damage the endothelium, the vein closes.
The biology is more complex.
Two important experimental studies help clarify what is really happening:
‘Implication of foam sclerosant inactivation by human whole blood in a laboratory setting’
and
‘Media Damage Following Detergent Sclerotherapy Appears to be Secondary to the Induction of Inflammation and Apoptosis: An Immunohistochemical Study Elucidating Previous Histological Observations.’
These papers demonstrate two critical realities.
- First, blood is not passive. It actively reduces sclerosant activity. Detergent agents rapidly bind to plasma proteins such as albumin, forming inactive complexes. Even small volumes of blood can significantly decrease the active fraction available to act on the vein wall.
- Second, durable vein closure depends on more than superficial endothelial injury. Successful treatment requires deeper medial damage driven by inflammatory and apoptotic pathways. If injury remains too superficial relative to wall thickness, recanalisation becomes more likely.
In simple terms:
- Blood reduces effective drug activity
- The vein wall response determines durability
- Endothelial irritation alone is not enough
Why this matters clinically ?
These mechanistic insights help explain why outcomes vary:
- Larger veins behave differently from smaller veins
- Technique influences drug–wall contact time
- Mixing with blood reduces effective concentration
- Wall thickness influences long-term closure
- Sclerotherapy is not just a chemical injection. It is a biological interaction between sclerosant, blood, and vessel wall.
Understanding that interaction helps us refine technique, counsel patients more accurately, and improve durability of results.
What changes, if any, have these mechanisms prompted in your own approach to sclerotherapy?”
Stay updated with Hemostasis Today.
-
Apr 10, 2026, 01:19Heghine Khachatryan: When Vascular Fragility Defines Risk – Rethinking Hemostasis in LDS
-
Apr 9, 2026, 21:39Mechanisms of Immune Dysregulation in Immune Thrombocytopenia – JTH
-
Apr 9, 2026, 21:37Arun V J: The Nation Inside the Human Body and Blood Function
-
Apr 9, 2026, 21:36José Antonio García Erce: Fall of While Blood Donation And Apheresis Growth in Spain
-
Apr 9, 2026, 21:34Chokri Ben Lamine: High-Yield Clinical Insights on Carfilzomib-Induced aHUS
-
Apr 9, 2026, 21:29Satyam Arora: Improving Thalassaemia Care in India Through Ground-Level Data
-
Apr 9, 2026, 20:33Pat Garcia-Gonzalez: On World Health Day, I’m thinking about what ‘health’ really means
-
Apr 9, 2026, 19:13Jan Sloves: Patterns and Pitfalls Influencing Treatment of Small Saphenous Vein Reflux
-
Apr 9, 2026, 18:38Jecko Thachil: Why D-dimers are Useful Tests for the Exclusion of Thromboembolism and the Diagnosis of DIC